Syngex Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.33 M
- Revenue Growth 107.19%
- Profit Growth 112.56%
- Ebitda 126.92%
- Net Worth 88.24%
- Total Assets 66.55%
About Syngex Pharma
Syngex Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 September 2018 (Six years and five months 19 days old ). Its registered office is in Guwahati, Assam, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.33 M.
Suman Das and Ranjeet Baruah serve as directors at the Company.
Company Details
- Location
Guwahati, Assam, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24100AS2018PTC018704
- Company No.
018704
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Sep 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Syngex Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suman Das  | Director | 05-Sep-2018 | Current |
| Ranjeet Baruah | Director | 05-Sep-2018 | Current |
Financial Performance of Syngex Pharma.
Syngex Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 107.19% increase. The company also saw a substantial improvement in profitability, with a 112.56% increase in profit. The company's net worth Soared by an impressive increase of 88.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Syngex Pharma?
In 2023, Syngex Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.33 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.03 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 May 2022 | Others | ₹0.33 M | Open |
How Many Employees Work at Syngex Pharma?
Syngex Pharma has a workforce of 20 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Syngex Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Syngex Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.